Argent Biopharma (AU:RGT) has released an update.
Argent BioPharma Ltd. is set to delist from the Australian Securities Exchange (ASX) due to low trading volume, difficulties in raising funds in Australia, and higher benefits perceived from its primary listing on the London Stock Exchange (LSE). Shareholders are advised on the steps required to transition their shares into Depositary Interests tradeable on the LSE, with the transition process involving a one-month notice after communication. The decision is also financially driven, with the goal of reallocating funds from listing costs to the company’s core operations.
For further insights into AU:RGT stock, check out TipRanks’ Stock Analysis page.
